Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria

NCT01732471 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Phenylketonuria

Interventions

DRUG: Kuvan®

Sponsor

Merck KGaA, Darmstadt, Germany